Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17548491 | 0.84 | ACMSD (1.00) | ACMSDKMT2ALMNAMAPTPKM | |
| SCHEMBL17548428 | 0.83 | ACMSD (0.71) | ACMSDHTTKMT2ALMNAGAA | |
| SCHEMBL32688002 | 0.82 | ACMSD (0.70) | ACMSDHTTKMT2ARAB9A | |
| SCHEMBL17553772 | 0.81 | ACMSD (0.69) | ACMSDHTTHDAC1KMT2ALMNA | |
| SCHEMBL17553551 | 0.81 | ACMSD (0.68) | ACMSDHTTKMT2AMAPTPKM | |
| SCHEMBL23849882 | 0.81 | ACMSD (0.67) | ACMSDKMT2AMAPTPKMTSHR | |
| SCHEMBL31053425 | 0.81 | ACMSD (0.67) | ACMSDKMT2AMAPTPKMTSHR | |
| SCHEMBL17548488 | 0.79 | ACMSD (1.00) | ACMSDKMT2ARAB9A | |
| SCHEMBL17548492 | 0.79 | ACMSD (1.00) | ACMSDKMT2ARAB9A | |
| SCHEMBL17550093 | 0.76 | ACMSD (1.00) | ACMSDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| EP-3186242-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-10-06 | — | — | EP | disclosed |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2020-07-02 | — | — | US | disclosed |
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2017-12-21 | — | — | US | disclosed |
| US-9708272-B2 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708272-B2 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2017-07-18 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| WO-2016030534-A1 | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885HTT 1861/4885HDAC1 937/4885 |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885HTT 1861/4885HDAC1 937/4885 |
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885HTT 1861/4885HDAC1 937/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885HTT 1861/4885HDAC1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.